ABSTRACT Background
INTRODUCTION
Pregnancy is associated with significant changes in maternal haemodynamics and measures of arterial stiffness across each trimester (1) . In particular, significant increases in arterial stiffness and wave reflection parameters are noted amongst pregnant women who subsequently develop pre-eclampsia and small for gestational age foetuses (2) , as well as those with known pre-eclampsia (3) . Cross-sectional studies(4-6) conducted in late pregnancy or immediately post-partum have suggested an independent link between arterial stiffness and gestational diabetes mellitus (GDM), with increased pulse wave velocity (PWV) and augmentation index (AIx) in GDM compared to women with normal glucose tolerance. Furthermore, GDM may be associated with chronic effects on vascular haemodynamics, impacting longer-term outcomes. Women with a history of GDM have evidence of endothelial dysfunction and are at increased risk of vascular complications independent of known risk factors (7, 8) . However, these studies are limited by sample size and are cross-sectional in nature. A clearer understanding of changes in arterial stiffness throughout pregnancy and post-partum between GDM and healthy women may be of predictive value.
Pregnancy-associated diabetes has historically only been treated with dietary modification and/or insulin. Metformin was also considered unsafe, as the drug crosses the placenta, posing a potential threat to the foetus. Glyburide, a sulphonylurea, was the second line treatment after Insulin in the US for GDM. However, it has now superseded insulin as the most common treatment since 2007; being used in over 64.5% of women with GDM (9) .
Though this change was due to the perception that Glyburide does not cross the placenta (10) , there have been reports of an increased rate of pre-eclampsia, neonatal jaundice requiring phototherapy, increased duration of stay in the neonatal unit, macrosomia and neonatal hypoglycaemia following its use (11) . Results from a systematic review and meta-analysis established that glyburide is inferior to both metformin and insulin in the treatment of women with GDM (12) . Results from several observational and randomised trials over the past decade have confirmed that metformin use in pregnancy is safe, with no evidence of increased birth defects or other pregnancy-related complications (13) (14) (15) (16) , though it remains unlicensed for use in pregnancy.
GDM is now treated with dietary and lifestyle modification, metformin and if needed insulin (17) . Metformin may have cardiovascular benefits (18) ; the UK Prospective Diabetes Study (UKPDS) demonstrating that metformin use in obese patients with type 2 diabetes is associated with beneficial effects on cardiovascular disease outcomes, with a 36% and 39% relative risk reduction in all-cause mortality and myocardial infarction, respectively (19) . In a randomised, placebo controlled trial, short-term metformin therapy was found to improve arterial stiffness and endothelial function in young women with polycystic ovarian syndrome (PCOS) (20) .
It is important to assess whether metformin use may be associated with potential benefits on vascular stiffness in GDM, as this may also be associated long-term cardiovascular benefit. Therefore, a pilot study was undertaken to assess i) longitudinal changes in maternal haemodynamics, including AIx and PWV parameters among pregnant women with GDM compared to healthy pregnancy; and ii) to explore whether metformin compared to diet-only modification had beneficial effects on maternal haemodynamic assessments.
METHODS
Fifty-six consecutive women with a singleton viable pregnancy attending their first appointment at the GDM clinic and a further 60 low-risk healthy pregnant women attending their routine antenatal dating ultrasound scan at the University Hospitals of Leicester NHS Trust, were invited to participate in the study. Screening for women at risk of GDM is always offered to pregnant women with: BMI greater than 30kg/m 2 , previous macrosomic baby weighing more than 4.5kg, previous history of GDM, family history of diabetes in a first degree relative, or of minority ethnic origin with a high prevalence of diabetes (17) .
Screening was offered at 24-28 weeks of gestation and diagnosis of GDM was made if the woman had either: a fasting plasma glucose level of 5.6 mmol/litre or above OR a 2-hour plasma glucose level of 7.8 mmol/litre or above (17) .
Women screening positive for GDM were included into the GDM group. Participants were excluded if they were current smokers, had a multiple pregnancy, foetal anomalies, prepregnancy or pregnancy-induced hypertension, pre-eclampsia, thyroid disease requiring medication, renal disease, type1 or 2 diabetes mellitus, GDM requiring insulin or were taking any medication that could affect the cardiovascular system. In addition, eligibility into the control group required the participants to have body mass index (BMI) between 18. Control, GDM-D and GDM-M groups at each of the four gestational windows and the estimated probabilities of 12 mean differences were subsequently adjusted by Bonferroni correction to account for multiple comparisons. For variables where the two-way interaction effect was not statistically significant, we did not conduct any treatment group comparison at the predefined time points.
All statistical tests were two-sided with type 1 error rate (p-value) of 0.05 to determine statistical significance. All statistical analyses were carried out using the R software version 3.3 with appropriate R packages (nlme, multcomp, ggplot2) (R Core Team, 2016).
RESULTS
A total of one hundred and sixteen women were recruited to the study; 56 women with GDM, of whom 33 of mean age 31.7 years (SD 5.4 years) were in the GDM-M group and 23
of mean age 33.1 years (4.7 years) were in the GDM-D group, and 60 women of mean age 29.7 years (SD 5.3 years) in the control group. Baseline characteristics are described in Table   1 .
Brachial Augmentation index
The fitted linear mixed model showed strong evidence of a two-way interaction effect between group (Control, GDM-D and GDM-M) and gestational stage (AN1, AN2, AN3 and PN) for brachial AIx (p=0.004) and aortic AIx (p=0.008) after adjusting for heart rate, central mean arterial pressure and baseline body weight. (Table 2 and Supplementary Tables 1 
Aortic augmentation index
Similar to brachial AIx , we also found strong evidence (p=0.008) of a two-way interaction effect between group (Control, GDM-D and GDM-M) and gestational stage (AN1, AN2, AN3
and PN) for aortic AIx following adjustment for baseline body weight, heart rate and central mean arterial pressure (Table 2 and Supplementary Tables 1 and 2 , Figure 2 
Pulse wave velocity
Only mean differences between gestational stages (p=0.003), not between groups (p=0.511), were statistically significant for PWV, after adjusting for baseline body weight, heart rate and systolic blood pressure (Table 2 and Supplementary Tables 1 and 2 , Figure 3 ).
The mean PWV values were significantly higher at AN2 (p=0.005) and PN (p=0.003) compared with the value at AN1, but the mean PWV at AN3 was not significantly different from the mean PWV at AN1 (p=0.458).
DISCUSSION
This longitudinal pilot study has demonstrated that pregnancies affected by GDM may be associated with significant alterations in maternal haemodynamics, as demonstrated by temporal changes in AIx, BP and PWV. Exploring the effect of metformin on maternal haemodynamics, we observed a potential interaction effect suggesting that metformin may attenuate the GDM associated AIx rise during the second trimester as demonstrated between 32-34 weeks of pregnancy.
Our study describes differences in arterial stiffness measurements over the course of GDM and normal glucose tolerant pregnancies. However, apart from AIx, there was no significant difference in arterial stiffness parameters between the GDM and control groups in pregnancy or postpartum. Further merit is given to this finding when the comparison is performed at PN. The GDM-M group would now not be on any therapy, as metformin is stopped on the day of delivery, yet we found a significant mean difference between the GDM-D and GDM-M vs the control group, with a marked increase in AIx in the GDM metformin group at PN. This trend could mean that metformin may offer a protective effect on the vasculature and once stopped, the protection ceases. This is in keeping with the understanding that AIx may reflect the early changes of arterial stiffness, as the changes are more prevalent in younger individuals (age<50years), whereas, PWV may reflect the later or chronic changes in arterial stiffness as age related changes are more marked in individuals over the age of 50 (22) . In addition, our results are in keeping with previous work demonstrating that AIx, increases with advancing gestational from 28 weeks of gestation to term (23) (24) (25) . The pattern of AIx in this study, however, demonstrates a unique alteration in the expected pattern, i.e., the metformin group had an improvement in the AIx at AN3. This potential atypical trend was only present during the time of metformin treatment and reverted to the expected pattern at PN when metformin was stopped. This further strengthens the proposed effects of metformin in this population group.
Savidou et al (6) found that in patients with GDM, mean (SD) AIx (a measure of arterial wave reflection) was significantly higher compared to healthy controls, (13.1 ± 8.9% vs 0.7 ± 11.4%; p<0.001), similarly, this study found a significant difference in the AIx values in women with GDM managed with metformin or diet modification in comparison to the control group . Our study found that at AN1, mean AIx was higher in the GDM-M group, 4.90% (11.02), in comparison to controls.
Savidou et al(6) also found that in patients with GDM the mean (SD) PWV was marginally increased compared to healthy controls (6.0 ± 1.5 vs 5.4 ± 0.6 m/s; p =0.070). Similarly, in our study we found that the mean PWV is higher in women with GDM, with the mean value in the GDM-D group being 8.54 m/s (1.51) and in the GDM-M group being 8.97 m/s (1.71), in comparison to 8.28m/s in the healthy control group. However, the differences were not statistically significant, p=0.494 (Figure2) . This re-affirms the findings from two previous studies(4, 5) which found that there was no significant difference in PWV between GDM and control groups. Additionally, we found that the mean difference between the stages of pregnancy was significant and observed that the pattern of PWV in the diet and healthy control group followed a pattern, grossly resembling a sine wave, similar to the findings of other studies of longitudinal changes of PWV during pregnancy (26, 27) .However, the metformin group did not demonstrate any such pattern. The PWV in the metformin group did not exhibit the characteristic reduction in the third trimester of pregnancy, remaining higher at AN3 and PN.
The current study has several strengths. We have used a well-defined inclusion and exclusion criteria to limit the effect of any maternal condition on haemodynamic parameters. We have longitudinal follow-up to make sure that changes are directly related to the same group. In comparison, Savvidou et al (6) , however, had a GDM population that had a significantly higher blood pressure than the control subjects, and this may have influenced the results within the GDM group, as it is understood that PWV in known to increase with BP, and BP is a recognised determinant of aortic PWV (28) (29) (30) . Equally, the control group in the study of Bulzico et al(5) had a higher prevalence of T2DM and cardiovascular disease in their first degree relatives(31), which may be associated with higher aortic stiffness(31). Throughout our study, BP in both groups over all the four time points remained within the normal range, however Central mean (SD) BP was significantly higher in the GDM group in comparison to the healthy control, 67.02mmHG (13.25) vs 61.25mmHG (9.57), p=0.02. Furthermore, Central diastolic BP and Central mean BP were significantly higher in the GDM metformin group compared to the healthy control group, p=0.01 and p=0.06, respectively. Therefore, it could be argued that the findings of an increased PWV in the GDM groups are a result of an increase in BP and possibly age.
We cannot fully explain the cause of this interesting observation which may allude to Metformin having pleiotrophic actions yet unknown to us, therefore more research is necessary. Even though we did not find that metformin had a significant effect on all maternal haemodynamic parameters in women with GDM, the mean difference (SD)
between the GDM-M and GDM-D groups for aortic AIx at AN3 was statistically significant The study has certain limitations. The small number of participants (n=56), however, an attempt to overcome this was made with the longitudinal assessment of women on four separate occasions. Unfortunately, loss to follow-up is an understood weakness of a longitudinal study, and the authors found a higher loss to follow up in the postnatal period.
This was attributed to the practical difficulties to a new mother in the puerperium. We 
